InflaRx NV

NAS:IFRX (Germany)  
$ 2.51 +0.01 (+0.4%) 11:08 PM EST
At Loss
P/B:
2.04
Market Cap:
$ 147.80M
Enterprise V:
$ 88.50M
Volume:
51.34K
Avg Vol (2M):
323.93K
Trade In:
Volume:
51.34K
At Loss
Avg Vol (2M):
323.93K

Business Description

Description
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
Name Current Vs Industry Vs History
Cash-To-Debt 64.44
Equity-to-Asset 0.82
Debt-to-Equity 0.01
Debt-to-EBITDA -0.02
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -1.61
Distress
Grey
Safe
Beneish M-Score 3.12
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 70.89
9-Day RSI 63.6
14-Day RSI 62.31
6-1 Month Momentum % 24.55
12-1 Month Momentum % 21.64

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 5.31
Quick Ratio 4.61
Cash Ratio 4.17
Days Inventory 4137.31
Days Sales Outstanding 106.54
Days Payable 4365.66

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -27.8
Shareholder Yield % 0.13

Financials (Next Earnings Date:2025-03-21 Est.)

IFRX's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:IFRX

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

InflaRx NV Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0.185
EPS (TTM) ($) -1.081
Beta 1.62
Volatility % 69.88
14-Day RSI 62.31
14-Day ATR ($) 0.228673
20-Day SMA ($) 2.3735
12-1 Month Momentum % 21.64
52-Week Range ($) 1.165 - 2.815
Shares Outstanding (Mil) 58.88

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

InflaRx NV Filings

Filing Date Document Date Form
No Filing Data

InflaRx NV Stock Events

Financials Calendars
Event Date Price($)
No Event Data

InflaRx NV Frequently Asked Questions

What is InflaRx NV(IFRX)'s stock price today?
The current price of IFRX is $2.51. The 52 week high of IFRX is $2.82 and 52 week low is $1.17.
When is next earnings date of InflaRx NV(IFRX)?
The next earnings date of InflaRx NV(IFRX) is 2025-03-21 Est..
Does InflaRx NV(IFRX) pay dividends? If so, how much?
InflaRx NV(IFRX) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1